N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes

Fibroproliferative diseases are responsible for 45% of deaths in the developed world. Curing organ fibrosis is essential for fibroproliferative diseases. Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction. However, therapy to comba...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanasaki, Keizo, Nagai, Takako, Nitta, Kyoko, Kitada, Munehiro, Koya, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995071/
https://www.ncbi.nlm.nih.gov/pubmed/24782774
http://dx.doi.org/10.3389/fphar.2014.00070
_version_ 1782312820523663360
author Kanasaki, Keizo
Nagai, Takako
Nitta, Kyoko
Kitada, Munehiro
Koya, Daisuke
author_facet Kanasaki, Keizo
Nagai, Takako
Nitta, Kyoko
Kitada, Munehiro
Koya, Daisuke
author_sort Kanasaki, Keizo
collection PubMed
description Fibroproliferative diseases are responsible for 45% of deaths in the developed world. Curing organ fibrosis is essential for fibroproliferative diseases. Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction. However, therapy to combat diabetic nephropathy has not yet been established. In this review, we discuss the novel therapeutic possibilities for kidney fibrosis in diabetes focusing on the endogenous anti-fibrotic peptide, N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), which is the substrate for angiotensin-converting enzyme and exhibits meaningful anti-fibrotic effects in various experimental models of fibrotic disease.
format Online
Article
Text
id pubmed-3995071
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-39950712014-04-29 N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes Kanasaki, Keizo Nagai, Takako Nitta, Kyoko Kitada, Munehiro Koya, Daisuke Front Pharmacol Pharmacology Fibroproliferative diseases are responsible for 45% of deaths in the developed world. Curing organ fibrosis is essential for fibroproliferative diseases. Diabetic nephropathy is a common fibroproliferative disease of the kidney and is associated with multiorgan dysfunction. However, therapy to combat diabetic nephropathy has not yet been established. In this review, we discuss the novel therapeutic possibilities for kidney fibrosis in diabetes focusing on the endogenous anti-fibrotic peptide, N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP), which is the substrate for angiotensin-converting enzyme and exhibits meaningful anti-fibrotic effects in various experimental models of fibrotic disease. Frontiers Media S.A. 2014-04-14 /pmc/articles/PMC3995071/ /pubmed/24782774 http://dx.doi.org/10.3389/fphar.2014.00070 Text en Copyright © 2014 Kanasaki, Nagai, Nitta, Kitada and Koya. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Kanasaki, Keizo
Nagai, Takako
Nitta, Kyoko
Kitada, Munehiro
Koya, Daisuke
N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
title N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
title_full N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
title_fullStr N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
title_full_unstemmed N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
title_short N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
title_sort n-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995071/
https://www.ncbi.nlm.nih.gov/pubmed/24782774
http://dx.doi.org/10.3389/fphar.2014.00070
work_keys_str_mv AT kanasakikeizo nacetylserylaspartyllysylprolineavaluableendogenousantifibroticpeptideforcombatingkidneyfibrosisindiabetes
AT nagaitakako nacetylserylaspartyllysylprolineavaluableendogenousantifibroticpeptideforcombatingkidneyfibrosisindiabetes
AT nittakyoko nacetylserylaspartyllysylprolineavaluableendogenousantifibroticpeptideforcombatingkidneyfibrosisindiabetes
AT kitadamunehiro nacetylserylaspartyllysylprolineavaluableendogenousantifibroticpeptideforcombatingkidneyfibrosisindiabetes
AT koyadaisuke nacetylserylaspartyllysylprolineavaluableendogenousantifibroticpeptideforcombatingkidneyfibrosisindiabetes

Ejemplares similares